- Home
- IMTX vs XERS Comparison
IMTX vs XERS Comparison
Compare IMTX & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMTX | XERS |
|---|---|---|
| Founded | N/A | 2005 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | IMTX | XERS |
|---|---|---|
| Price | $9.16 | $7.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $19.25 | $10.43 |
| AVG Volume (30 Days) | 464.2K | ★ 2.5M |
| Earning Date | 11-17-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $99,445,031.00 | ★ $266,137,000.00 |
| Revenue This Year | N/A | $44.37 |
| Revenue Next Year | $19.39 | $27.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 42.05 |
| 52 Week Low | $3.30 | $3.14 |
| 52 Week High | $12.41 | $10.08 |
Technical Indicators
Market Signals| Indicator | IMTX | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 39.70 | 59.07 |
| Support Level | $9.13 | $6.88 |
| Resistance Level | $10.19 | $8.42 |
| Average True Range (ATR) | 0.49 | 0.41 |
| MACD | -0.12 | 0.10 |
| Stochastic Oscillator | 13.78 | 69.73 |
Price Performance
Historical ComparisonAbout IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).